L
Laurens F. Reeskamp
Researcher at University of Amsterdam
Publications - 39
Citations - 867
Laurens F. Reeskamp is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Familial hypercholesterolemia & Medicine. The author has an hindex of 10, co-authored 30 publications receiving 326 citations.
Papers
More filters
Journal ArticleDOI
Evinacumab for Homozygous Familial Hypercholesterolemia
Frederick J. Raal,Robert S. Rosenson,Laurens F. Reeskamp,G. Kees Hovingh,John J.P. Kastelein,Paolo Rubba,Shazia Ali,Poulabi Banerjee,Kuo-Chen Chan,Daniel A. Gipe,Nagwa Khilla,Robert Pordy,David M. Weinreich,George D. Yancopoulos,Yi Zhang,Daniel Gaudet +15 more
TL;DR: In patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy, the reduction from baseline in the LDL cholesterol level in the evinacumab group, as compared with the small increase in the placebo group, resulted in a between-group difference of 49.0 percentage points at 24 weeks.
Journal ArticleDOI
Combination lipid-lowering therapy as first-line strategy in very high-risk patients.
Kausik K. Ray,Laurens F. Reeskamp,Ulrich Laufs,Maciej Banach,François Mach,Lale Tokgozoglu,Derek L. Connolly,Anja J Gerrits,Erik S.G. Stroes,Luis Masana,John J.P. Kastelein +10 more
Journal ArticleDOI
ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report.
Laurens F. Reeskamp,John S. Millar,Liya Wu,Hans Jansen,Dewi van Harskamp,Henk Schierbeek,Daniel A. Gipe,Daniel J. Rader,Geesje M. Dallinga-Thie,G. Kees Hovingh,Marina Cuchel +10 more
TL;DR: In this article, the authors investigated apoB (apolipoprotein B) containing lipoprotein kinetic parameters in patients with homozygous familial hypercholesterolemia, before and after treatment with evinacumab.
Journal ArticleDOI
Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.
Laurens F. Reeskamp,John J.P. Kastelein,Patrick M. Moriarty,P. Barton Duell,Alberico L. Catapano,Raul D. Santos,Christie M. Ballantyne +6 more
TL;DR: The thrice-weekly dosing regimen was associated with lower frequency of flu-like symptoms, which might help avert discontinuation in some patients, but otherwise had no major benefits.
Journal ArticleDOI
Transintestinal cholesterol excretion in humans
TL;DR: TICE contributes significantly to FNS excretion in humans, independently of the biliary pathway, and might be an interesting therapeutic target for increasing cholesterol disposal with the feces.